MARIETTA, Ga., Sept. 19, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today it will be hosting a webcast on Thursday, September 21, 2017 beginning at 10:30 a.m. Eastern Time to discuss numerous strategic initiatives and provide in-depth information on other key topics requested by shareholders.
The Company reported that “Pete” Petit, Chairman and CEO; Bill Taylor, President and COO; Chris Cashman, EVP and Chief Commercialization Officer; and Debbie Dean, Executive Vice President, will be presenting during the September 21st call.
The Company expects the planned presentation to last approximately 45 minutes. After the planned presentation, the call will be open for questions and answers. The subject matter, topics and updates to be covered during the formal presentation include: 
- Short Selling Matters and Proactive Remedies
- Patent and Intellectual Property Matters
- IND and BLA Clinical Studies
- Biopharma Market Valuations and Revenue Opportunities
- Additional Revenue Opportunity from VLU Clinical Study
A listen-only simulcast of this MiMedx shareholder call and presentation slides will be available on-line at the Company’s website at www.mimedx.com beginning at 10:30 a.m. eastern time, September 21, 2017. A 30-day on-line replay will be available approximately one hour following the conclusion of the live broadcast on the Company’s website at www.mimedx.com.
About MiMedx
MiMedx® is the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. “Innovations in Regenerative Medicine” is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of placental tissue, having supplied over 1,000,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.
SOURCE MiMedx Group, Inc.